A Biomimetic Nanovesicle‐Based Synthetic Vaccine Platform Through Co‐Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice
Angewandte Chemie International Edition · 20.04.2026 · 65 (17)
DOI: 10.1002/anie.202522249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 10.03.2026. Verfasst von Fengze Miao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Phospholipids, Biomimetic Materials, Oligodeoxyribonucleotides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Despite advances in immunotherapy, the efficacy against melanoma remains limited in aged individuals, primarily due to diminished dendritic cell (DC) function and an immunosuppressive tumor microenvironment. To address this, we report a chemically engineered “tumor ghost” nanovaccine (dMVac) constructed through a biomimetic synthesis strategy. The core nanovesicles are derived from separate melanoma cells subjected to hypochlorous acid oxidation and UVB radiation, respectively, enriching them with a broad spectrum of tumor antigens and endogenous damage‐associated molecular patterns. These nanovesicles are further functionalized via lipid‐insertion chemistry to co‐anchor the DC‐hyperactivating molecules: the oxidized phospholipid PGPC and cholesterol‐conjugated CpG oligonucleotide. This surface engineering enables efficient lymph node targeting and promotes synergistic DC activation. The resulting dMVac reverses age‐related DC dysfunction by enhancing their activation, migration, and IL‐1β secretion, thereby stimulating robust cytotoxic T‐cell responses and memory formation in aged mice. Moreover, dMVac synergizes with doxorubicin (DOX) and anti‐PD‐1 therapy to reprogram the immunosuppressive tumor microenvironment via enhanced antigen presentation and T‐cell infiltration, leading to significant suppression of tumor progression. This work demonstrates how rational chemical design of a bio‑hybrid nanovaccine can overcome age‐associated immune dysfunction, providing a versatile platform for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Shanghai Engineering Research Center of Topical Chinese Medicine, Shanghai, China.
ORCID-Profile: Zhongjian Chen
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Miao, F., Lu, J., Zhao, Y., Wang, W., Zhang, T., Liu, J., Zhang, X., Wu, L., Yan, H., Wang, R., Tai, Z., Chen, Z., & Zhu, Q. (2026). A Biomimetic Nanovesicle‐Based Synthetic Vaccine Platform Through Co‐Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice. Angewandte Chemie International Edition, 65(17). https://doi.org/10.1002/anie.202522249
Vancouver
Miao F, Lu J, Zhao Y, Wang W, Zhang T, Liu J, et al. A Biomimetic Nanovesicle‐Based Synthetic Vaccine Platform Through Co‐Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice. Angewandte Chemie International Edition. 2026;65(17). doi:10.1002/anie.202522249
BibTeX
@article{Miao2026,
author = {Miao, Fengze and Lu, Jiaye and Zhao, Yingchao and Wang, Weifan and Zhang, Tingrui and Liu, Jun and Zhang, Xinyue and Wu, Ling and Yan, Han and Wang, Ruyi and Tai, Zongguang and Chen, Zhongjian and Zhu, Quangang},
title = {A Biomimetic Nanovesicle‐Based Synthetic Vaccine Platform Through Co‐Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice},
journal = {Angewandte Chemie International Edition},
year = {2026},
volume = {65},
number = {17},
doi = {10.1002/anie.202522249}
}
EUVIMED